The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women.
Fabry disease is a rare X-linked lysosomal storage disorder caused by deficient activity of alpha-galactosidase A (alpha-Gal A) resulting in the storage of glycosphingolipids, especially globotriaosylceramide (Gb3), in cells throughout the body, causing life-threatening renal, cardiac, and cerebrovascular complications in hemizygous males and some heterozygous females. Disease manifestations in heterozygotes are being recognized increasingly, but quantitative prospective data on their extent and severity are limited. Prospective clinical and laboratory assessments were performed in a 7-day study of 61 women with signs and symptoms of Fabry disease. Analyses included medical history and physical, neurologic, cardiac, and ophthalmologic assessments; laboratory assessments; renal function tests; magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA) of the head; and Fabry-related blood and urine tests, including Gb3 levels in blood and urine, skin biopsies, and DNA genotype analysis of the alpha-Gal A gene to identify causative mutations. Quality of life, pain and concomitant medication were documented using validated questionnaires and diaries. All patients had normal Gb3 levels in plasma; only 1 patient had visible storage material in the superficial dermal vascular endothelial cells. Cardiac, renal, or cerebrovascular abnormalities were documented in 52 of the 57 patients (91%) with confirmed Fabry genotypes. These included electrocardiographic abnormalities in 38 of 52 patients (73%), echocardiographic abnormalities in 8 of 57 (14%), proteinuria (>150 g protein/24-h urine) in 23 of 38 (61%), low estimated glomerular filtration rate (<90 mL/min per 1.73 m) in 24 of 57 (42%), abnormal MRI in 4 of 54 (7%), and abnormal MRA in 10 of 50 patients (20%). Angiokeratomas and corneal epitheliopathy were documented in 63% and 82% of the 57 patients, respectively. Despite the virtual absence of storage material in plasma and skin vascular endothelial cells, this population of women with Fabry disease exhibited a wide spectrum of clinical abnormalities. Useful outcome measures for assessment of specific therapies need to be developed. Studies limited to homogeneously affected subjects may be possible.
Gupta
Surya
S
From Developmental and Metabolic Neurology Branch (SG, MR, RS), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland and Genzyme Corporation (SK), Cambridge, Massachusetts.
Ries
Markus
M
Kotsopoulos
Steven
S
Schiffmann
Raphael
R
D000328:Adult; D001808:Blood Vessels / Q000002:abnormalities* / Q000201:enzymology; D001921:Brain / Q000002:abnormalities; D018376:Cardiovascular Abnormalities / Q000175:diagnosis* / Q000201:enzymology; D003430:Cross-Sectional Studies; D000795:Fabry Disease / Q000201:enzymology / Q000235:genetics / Q000503:physiopathology*; D005260:Female; D005919:Glomerular Filtration Rate; D006028:Glycosphingolipids / Q000378:metabolism*; D006579:Heterozygote; D006801:Humans; D007668:Kidney / Q000002:abnormalities; D008875:Middle Aged; D011446:Prospective Studies; D011795:Surveys and Questionnaires; D014281:Trihexosylceramides / Q000378:metabolism* / Q000652:urine
D006028:Glycosphingolipids; D014281:Trihexosylceramides; C018549:globotriaosylceramide